Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Dicot Pharma ABFRA:KN0 +5.38%19 EV-to-EBIT is -7.98 as of Sep. 02, 2026. GuruFocus rates FRA:KN0 with a GF Score™ of 19/100. The stock has 1 warning sign investors should review. Among 683 Drug Manufacturers companies, Dicot Pharma AB ranks worse than 146412.74% on this metric.
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
Dicot Pharma AB's Enterprise Value for the quarter that ended in Jun. 2026 was €18.62 Mil.
Dicot Pharma AB's EBIT for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €-6.14 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Dicot Pharma AB EV-to-EBIT Related Terms
Dicot Pharma AB EV-to-EBIT Historical Data
* Premium members only.
The historical data trend for Dicot Pharma AB's EV-to-EBIT can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Dicot Pharma AB's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Dicot Pharma AB EV-to-EBIT vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Dicot Pharma AB's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Dicot Pharma AB's EV-to-EBIT falls into.
Dicot Pharma AB's current Enterprise Value is €48.99 Mil.
Dicot Pharma AB's EBIT for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €-6.14 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Dicot Pharma AB (FRA:KN0) has a EV-to-EBIT of -7.98 as of Sep. 02, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Dicot Pharma AB and its competitors. According to the industry distribution chart, Dicot Pharma AB ranks #999999 out of 683 companies in the Drug Manufacturers industry.
Is Dicot Pharma AB's EV-to-EBIT too high?
Dicot Pharma AB's current EV-to-EBIT is -7.98. Based on the distribution chart, Dicot Pharma AB ranks #999999 out of 683 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Dicot Pharma AB has a GF Score™ of 19/100, reflecting its overall financial health beyond just this single metric.
How does Dicot Pharma AB's EV-to-EBIT compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Dicot Pharma AB ranks #999999 out of 683 companies for EV-to-EBIT. This places Dicot Pharma AB in the lower half of its industry. The industry median EV-to-EBIT is 16.09. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Drug Manufacturers company?
The median EV-to-EBIT among Drug Manufacturers companies is 16.09, based on 683 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Dicot Pharma AB and its competitors. For the Drug Manufacturers industry, the median EV-to-EBIT is 16.09 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Dicot Pharma AB's current EV-to-EBIT is -7.98. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Dicot Pharma AB stock overvalued right now?
Dicot Pharma AB (FRA:KN0) has a current EV-to-EBIT of -7.98. The current EV-to-EBIT is -7.98. Dicot Pharma AB's overall GF Score™ is 19/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For Dicot Pharma AB (FRA:KN0), the current EV-to-EBIT is -7.98 as of Sep. 02, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Dicot Pharma AB is developing a modern potency medicine that will treat erectile dysfunction and premature ejaculation than existing preparations. The business model involves evaluating industrial and financial partnerships during clinical development to bring LIB-01 to commercialization on the world market. The company's drug candidate LIB-01 has a longer duration of action and fewer side effects, and is also used in the treatment of erectile dysfunction and premature ejaculation.
19GF Score
Get the complete analysis for FRA:KN0
EV-to-EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:KN0 has been successfully added to your 
